Base de dados : MEDLINE
Pesquisa : N03.349.315 [Categoria DeCS]
Referências encontradas : 3965 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 397 ir para página                         

  1 / 3965 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29156187
[Au] Autor:Ryan DH; Kahan S
[Ad] Endereço:Pennington Biomedical Research Center, 6400 Perkins Road, Baton Rouge, LA 70130, USA. Electronic address: ryandh@pbrc.edu.
[Ti] Título:Guideline Recommendations for Obesity Management.
[So] Source:Med Clin North Am;102(1):49-63, 2018 Jan.
[Is] ISSN:1557-9859
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:It is an obligation for all health care providers to participate in obesity management. This article discusses obesity guidelines from The Obesity Society; the Endocrine Society; and the American Association of Clinical Endocrinologists. It reviews and compares findings and recommendations across these guidelines, identifies areas of controversy and concordance, and suggests how primary care practices may make use of the most appropriate recommendations for their circumstances.
[Mh] Termos MeSH primário: Obesidade/terapia
Guias de Prática Clínica como Assunto
Atenção Primária à Saúde/organização & administração
[Mh] Termos MeSH secundário: Gerenciamento Clínico
Feminino
Diretrizes para o Planejamento em Saúde
Seres Humanos
Estilo de Vida
Masculino
Obesidade/diagnóstico
Perda de Peso
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171212
[Lr] Data última revisão:
171212
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171121
[St] Status:MEDLINE


  2 / 3965 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29045452
[Au] Autor:Hequet D; Callens C; Gentien D; Albaud B; Mouret-Reynier MA; Dubot C; Cottu P; Huchon C; Zilberman S; Berseneff H; Foa C; Salmon R; Roulot A; Lerebours F; Salomon A; Ghali N; Morel P; Li Q; Cayre A; Guinebretière JM; Hornberger J; Penault-Llorca F; Rouzier R
[Ad] Endereço:Department of Surgical Oncology, Institut Curie-Centre René Huguenin, St Cloud, France.
[Ti] Título:Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers.
[So] Source:PLoS One;12(10):e0185753, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: The Prosigna® breast cancer prognostic gene signature assay identifies a gene-expression profile that permits the classification of tumors into subtypes and gives a score for the risk of recurrence (ROR) at 10 years. The primary objective of this multicenter study was to evaluate the impact of Prosigna's assay information on physicians' adjuvant treatment decisions in patients with early-stage breast cancer. Secondary objectives were to assess confidence of practitioners in their therapeutic recommendations before and after the added information provided by the Prosigna assay; and to evaluate the emotional state of patients before and after the Prosigna test results. METHODS: Consecutive patients with invasive early-stage breast cancer were enrolled in a prospective, observational, multicenter study carried out in 8 hospitals in France. The Prosigna test was carried out on surgical specimens using the nCounter® Analysis System located at the Institut Curie. Both before and after receiving the Prosigna test results, physicians completed treatment confidence questionnaires and patients completed questionnaires concerning their state of anxiety, the difficulties felt in face of the therapy and quality of life. Information was also collected at 6 months regarding the physicians' opinion on the test results and the patients' degree of anxiety, difficulties with therapy and quality of life. RESULTS: Between March 2015 and January 2016, 8 study centers in France consecutively enrolled 210 postmenopausal women with estrogen receptor (ER) positive, human epidermal growth hormone-2 (HER-2) negative, and node negative tumors, either stage 1 or stage 2. Intrinsic tumor subtypes as assessed by the Prosigna test were 114 (58.2%) Luminal A, 79 (40.3%) Luminal B, 1 (0.5%) HER-2 enriched (HER-2E), and 2 (1.0%) basal-like. Before receiving the Prosigna test results, physicians categorized tumor subtypes based on immunohistochemistry (IHC) as Luminal A in 126 (64%) patients and Luminal B in 70 (36%) patients, an overall discordance rate of 25%. The availability of Prosigna assay results was significantly associated with the likelihood of change in treatment recommendations, with 34 patients (18%) having their treatment plan changed from Adjuvant Chemotherapy to No Adjuvant Chemotherapy or vice versa (p<0.001, Fisher's exact test). Prosigna test results also decreased patients' anxiety about the chosen adjuvant therapy, and improved emotional well-being and measures of personal perceptions of uncertainty. CONCLUSIONS: The results of this prospective decision impact study are consistent with 2 previous, identically designed studies carried out in Spain and Germany. The availability of Prosigna test results increased the confidence of treating physicians in their adjuvant treatment decisions, and led to an 18% change in chemotherapy treatment plan (from Adjuvant Chemotherapy to No Adjuvant Chemotherapy or vice versa). Prosigna testing decreased anxiety and improved measures of health-related quality of life in patients facing adjuvant therapy. The 25% discordance between Prosigna test and IHC subtyping underlines the importance of molecular testing for optimal systemic therapy indications in early breast cancer.
[Mh] Termos MeSH primário: Neoplasias da Mama/diagnóstico
Neoplasias da Mama/patologia
[Mh] Termos MeSH secundário: Neoplasias da Mama/tratamento farmacológico
Quimioterapia Adjuvante
Feminino
França
Diretrizes para o Planejamento em Saúde
Seres Humanos
Meia-Idade
Recidiva Local de Neoplasia/patologia
Estadiamento de Neoplasias
Médicos
Estudos Prospectivos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; OBSERVATIONAL STUDY
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171019
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0185753


  3 / 3965 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28987134
[Au] Autor:Paul CL; Ishiguchi P; D'Este CA; Shaw JE; Sanson-Fisher RW; Forshaw K; Bisquera A; Robinson J; Koller C; Eades SJ
[Ad] Endereço:University of Newcastle, Newcastle, NSW chris.paul@newcastle.edu.au.
[Ti] Título:Testing for type 2 diabetes in Indigenous Australians: guideline recommendations and current practice.
[So] Source:Med J Aust;207(5):206-210, 2017 Aug 04.
[Is] ISSN:1326-5377
[Cp] País de publicação:Australia
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To determine the proportion of Aboriginal Controlled Community Health Service (ACCHS) patients tested according to three national diabetes testing guidelines; to investigate whether specific patient characteristics were associated with being tested. DESIGN, SETTING AND PARTICIPANTS: Cross-sectional study of 20 978 adult Indigenous Australians not diagnosed with diabetes attending 18 ACCHSs across Australia. De-identified electronic whole service data for July 2010 - June 2013 were analysed. MAIN OUTCOMES MEASURES: Proportions of patients appropriately screened for diabetes according to three national guidelines for Indigenous Australians: National Health and Medical Research Council (at least once every 3 years for those aged 35 years or more); Royal Australian College of General Practitioners and Diabetes Australia (at least once every 3 years for those aged 18 years or more); National Aboriginal Community Controlled Health Organisation (annual testing of those aged 18 years or more at high risk of diabetes). RESULTS: 74% (95% CI, 74-75%) of Indigenous adults and 77% (95% CI, 76-78%) of 10 760 patients aged 35 or more had been tested for diabetes at least once in the past 3 years. The proportions of patients tested varied between services (range: all adults, 16-90%; people aged 35 years or more, 23-92%). 18% (95% CI, 18-19%) of patients aged 18 or more were tested for diabetes annually (range, 0.1-43%). Patients were less likely to be tested if they were under 50 years of age, were transient rather than current patients of the ACCHS, or attended the service less frequently. CONCLUSIONS: Some services achieved high rates of 3-yearly testing of Indigenous Australians for diabetes, but recommended rates of annual testing were rarely attained. ACCHSs may need assistance to achieve desirable levels of testing.
[Mh] Termos MeSH primário: Serviços de Saúde Comunitária/utilização
Diabetes Mellitus Tipo 2/diagnóstico
Grupo com Ancestrais Oceânicos/estatística & dados numéricos
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Austrália/epidemiologia
Austrália/etnologia
Serviços de Saúde Comunitária/métodos
Estudos Transversais
Diabetes Mellitus Tipo 2/epidemiologia
Feminino
Diretrizes para o Planejamento em Saúde
Seres Humanos
Masculino
Programas de Rastreamento/métodos
Programas de Rastreamento/estatística & dados numéricos
Meia-Idade
Medição de Risco
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171017
[Lr] Data última revisão:
171017
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171009
[St] Status:MEDLINE


  4 / 3965 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
[PMID]:28632831
[Au] Autor:Diomedi A; Chacón E; Delpiano L; Hervé B; Jemenao MI; Medel M; Quintanilla M; Riedel G; Tinoco J; Cifuentes M
[Ad] Endereço:Hospital Clínico, Mutual de Seguridad C.Ch.C., Santiago, Chile.
[Ti] Título:[Antiseptics and disinfectants: aiming at rational use. Recommendations of the Advisory Committee on Healthcare Associated Infections. Sociedad Chilena de Infectología].
[Ti] Título:Antisépticos y desinfectantes: apuntando al uso racional. Recomendaciones del Comité Consultivo de Infecciones Asociadas a la Atención de Salud, Sociedad Chilena de Infectología..
[So] Source:Rev Chilena Infectol;34(2):156-174, 2017 Apr.
[Is] ISSN:0717-6341
[Cp] País de publicação:Chile
[La] Idioma:spa
[Ab] Resumo:Proper use of antiseptics and disinfectants, is an essential tool to prevent the spread of infectious agents and to control of healthcare-associated infections (HAI). Given the increasing importance of environmental aspects, as well as several advances and updates in the field of its proper use at local and intemational level, the SOCHINF HAI Advisory Committee considers that it is necessary to develop a guide for the rational use of antiseptics and disinfectants, which it will provide consistent scientific basis with that purpose.
[Mh] Termos MeSH primário: Comitês Consultivos
Anti-Infecciosos Locais/administração & dosagem
Infecção Hospitalar/prevenção & controle
Desinfetantes/administração & dosagem
Sociedades Médicas
[Mh] Termos MeSH secundário: Chile
Higiene das Mãos
Diretrizes para o Planejamento em Saúde
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; PRACTICE GUIDELINE
[Nm] Nome de substância:
0 (Anti-Infective Agents, Local); 0 (Disinfectants)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170726
[Lr] Data última revisão:
170726
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170621
[St] Status:MEDLINE


  5 / 3965 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28573408
[Au] Autor:Donihi AC
[Ad] Endereço:Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy & University of Pittsburgh Medical Center (UPMC), MUH NE Suite 628, 200 Lothrop Street, Pittsburgh, PA, 15213, USA. amydonihi@pitt.edu.
[Ti] Título:Practical Recommendations for Transitioning Patients with Type 2 Diabetes from Hospital to Home.
[So] Source:Curr Diab Rep;17(7):52, 2017 Jul.
[Is] ISSN:1539-0829
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE OF REVIEW: The purpose of this review is to provide practical evidence-based recommendations for transitioning hospitalized patients with type 2 diabetes (T2DM) to home. RECENT FINDINGS: Hospitalized patients who have newly diagnosed or poorly controlled T2DM require initiation or intensification of their outpatient diabetes regimen. Potential barriers to medication access and continuity of care should be identified early in the hospitalization. Throughout hospitalization, patients should receive diabetes education focused on basic survival skills and tailored to learning needs. Patients should leave the hospital with personalized discharge instructions that include a list of all medications and follow-up appointments with both the outpatient diabetes provider and a diabetes educator whenever possible. An approach to transitioning patients with T2DM from hospital to home that focuses on optimizing the patient's discharge diabetes regimen, anticipating patients' needs during the immediate post-discharge period, providing survival skills education, and ensuring continuation of diabetes care and education following hospital discharge has the potential to improve glycemic control and reduce emergency department visits and hospital readmissions.
[Mh] Termos MeSH primário: Diabetes Mellitus Tipo 2/terapia
Diretrizes para o Planejamento em Saúde
Serviços de Assistência Domiciliar
Alta do Paciente
[Mh] Termos MeSH secundário: Educação em Saúde
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170603
[St] Status:MEDLINE
[do] DOI:10.1007/s11892-017-0876-1


  6 / 3965 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28355612
[Au] Autor:Alotaibi BM; Yezli S; Bin Saeed AA; Turkestani A; Alawam AH; Bieh KL
[Ad] Endereço:Global Center for Mass Gathering Medicine, Ministry of Health, Riyadh, Saudi Arabia.
[Ti] Título:Strengthening health security at the Hajj mass gatherings: characteristics of the infectious diseases surveillance systems operational during the 2015 Hajj.
[So] Source:J Travel Med;24(3), 2017 May 01.
[Is] ISSN:1708-8305
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Background: Hajj is one of the largest and the most ethnically and culturally diverse mass gatherings worldwide. The use of appropriate surveillance systems ensures timely information management for effective planning and response to infectious diseases threats during the pilgrimage. The literature describes infectious diseases prevention and control strategies for Hajj but with limited information on the operations and characteristics of the existing Hajj infectious diseases surveillance systems. Method: We reviewed documents, including guidelines and reports from the Saudi Ministry of Health's database, to describe the characteristics of the infectious diseases surveillance systems that were operational during the 2015 Hajj, highlighting best practices and gaps and proposing strategies for strengthening and improvement. Using Pubmed and Embase online search engines and a combination of search terms including, 'mass gatherings' 'Olympics' 'surveillance' 'Hajj' 'health security', we explored the existing literature and highlighted some lessons learnt from other international mass gatherings. Results: A regular indicator-based infectious disease surveillance system generates routine reports from health facilities within the Kingdom to the regional and central public health directorates all year round. During Hajj, enhanced indicator-based notifiable diseases surveillance systems complement the existing surveillance tool to ensure timely reporting of event information for appropriate action by public health officials. Conclusion: There is need to integrate the existing Hajj surveillance data management systems and to implement syndromic surveillance as an early warning system for infectious disease control during Hajj. International engagement is important to strengthen Hajj infectious diseases surveillance and to prevent disease transmission and globalization of infectious agents which could undermine global health security.
[Mh] Termos MeSH primário: Controle de Doenças Transmissíveis/métodos
Doenças Transmissíveis/epidemiologia
Surtos de Doenças/prevenção & controle
Diretrizes para o Planejamento em Saúde
[Mh] Termos MeSH secundário: Seres Humanos
Islamismo
Vigilância da População/métodos
Arábia Saudita/epidemiologia
Viagem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170901
[Lr] Data última revisão:
170901
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170330
[St] Status:MEDLINE
[do] DOI:10.1093/jtm/taw087


  7 / 3965 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28327187
[Au] Autor:Colley DG; Andros TS; Campbell CH
[Ad] Endereço:Schistosomiasis Consortium for Operational Research and Evaluation (SCORE), Center for Tropical and Emerging Global Diseases (CTEGD), University of Georgia, 500 DW Brooks Drive, Room 330B Coverdell Center, Athens, Georgia, 30602, USA. dcolley@uga.edu.
[Ti] Título:Schistosomiasis is more prevalent than previously thought: what does it mean for public health goals, policies, strategies, guidelines and intervention programs?
[So] Source:Infect Dis Poverty;6(1):63, 2017 Mar 22.
[Is] ISSN:2049-9957
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Mapping and diagnosis of infections by the three major schistosome species (Schistosoma haematobium, S. mansoni and S. japonicum) has been done with assays that are known to be specific but increasingly insensitive as prevalence declines or in areas with already low prevalence of infection. This becomes a true challenge to achieving the goal of elimination of schistosomiasis because the multiplicative portion of the life-cycle of schistosomes, in the snail vector, favors continued transmission as long as even a few people maintain low numbers of worms that pass eggs in their excreta. New mapping tools based on detection of worm antigens (circulating cathodic antigen - CCA; circulating anodic antigen - CAA) in urine of those infected are highly sensitive and the CAA assay is reported to be highly specific. Using these tools in areas of low prevalence of all three of these species of schistosomes has demonstrated that more people harbor adult worms than are regularly excreting eggs at a level detectable by the usual stool assay (Kato-Katz) or by urine filtration. In very low prevalence areas this is sometimes 6- to10-fold more. Faced with what appears to be a sizable population of "egg-negative/worm-positive schistosomiasis" especially in areas of very low prevalence, national NTD programs are confounded about what guidelines and strategies they should enact if they are to proceed toward a goal of elimination. There is a critical need for continued evaluation of the assays involved and to understand the contribution of this "egg-negative/worm-positive schistosomiasis" condition to both individual morbidity and community transmission. There is also a critical need for new guidelines based on the use of these more sensitive assays for those national NTD programs that wish to move forward to strategies designed for elimination.
[Mh] Termos MeSH primário: Saúde Pública/métodos
Esquistossomose/epidemiologia
Esquistossomose/prevenção & controle
[Mh] Termos MeSH secundário: Animais
Fezes/parasitologia
Diretrizes para o Planejamento em Saúde
Política de Saúde
Seres Humanos
Prevalência
Administração em Saúde Pública/métodos
Caramujos/parasitologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170426
[Lr] Data última revisão:
170426
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170323
[St] Status:MEDLINE
[do] DOI:10.1186/s40249-017-0275-5


  8 / 3965 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28286108
[Au] Autor:Zignego AL; Ramos-Casals M; Ferri C; Saadoun D; Arcaini L; Roccatello D; Antonelli A; Desbois AC; Comarmond C; Gragnani L; Casato M; Lamprecht P; Mangia A; Tzioufas AG; Younossi ZM; Cacoub P; ISG-EHCV
[Ad] Endereço:Interdepartmental Center for Systemic Manifestations of Hepatitis Viruses (MaSVE), Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. Electronic address: annalinda.zignego@unifi.it.
[Ti] Título:International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement.
[So] Source:Autoimmun Rev;16(5):523-541, 2017 May.
[Is] ISSN:1873-0183
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Hepatitis C virus (HCV) is both hepatotrophic and lymphotropic virus that causes liver as well extrahepatic manifestations including cryoglobulinemic vasculitis, the most frequent and studied condition, lymphoma, and neurologic, cardiovascular, endocrine-metabolic or renal diseases. HCV-extrahepatic manifestations (HCV-EHMs) may severely affect the overall prognosis, while viral eradication significantly reduces non-liver related deaths. Different clinical manifestations may coexist in the same patient. Due to the variety of HCV clinical manifestations, a multidisciplinary approach along with appropriate therapeutic strategies are required. In the era of interferon-free anti-HCV treatments, international recommendations for the therapeutic management of HCV-EHMs are needed. This implies the need to define the best criteria to use antivirals and/or other therapeutic approaches. The present recommendations, based on qualified expert experience and specific literature, will focus on etiological (antiviral) therapies and/or traditional pathogenetic treatments that still maintain their therapeutic utility.
[Mh] Termos MeSH primário: Antivirais/uso terapêutico
Diretrizes para o Planejamento em Saúde
Hepacivirus/metabolismo
Hepatite C/complicações
[Mh] Termos MeSH secundário: Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antiviral Agents)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170918
[Lr] Data última revisão:
170918
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170314
[St] Status:MEDLINE


  9 / 3965 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27863363
[Au] Autor:Benzer W; Rauch B; Schmid JP; Zwisler AD; Dendale P; Davos CH; Koudi E; Simon A; Abreu A; Pogosova N; Gaita D; Miletic B; Bönner G; Ouarrak T; McGee H; EuroCaReD study group
[Ad] Endereço:Reha Sports Institute and Case Management Centre, Feldkirch, Austria. Electronic address: wbenzer@cable.vol.at.
[Ti] Título:Exercise-based cardiac rehabilitation in twelve European countries results of the European cardiac rehabilitation registry.
[So] Source:Int J Cardiol;228:58-67, 2017 Feb 01.
[Is] ISSN:1874-1754
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:AIM: Results from EuroCaReD study should serve as a benchmark to improve guideline adherence and treatment quality of cardiac rehabilitation (CR) in Europe. METHODS AND RESULTS: Data from 2.054 CR patients in 12 European countries were derived from 69 centres. 76% were male. Indication for CR differed between countries being predominantly ACS in Switzerland (79%), Portugal (62%) and Germany (61%), elective PCI in Greece (37%), Austria (36%) and Spain (32%), and CABG in Croatia and Russia (36%). A minority of patients presented with chronic heart failure (4%). At CR start, most patients already were under medication according to current guidelines for the treatment of CV risk factors. A wide range of CR programme designs was found (duration 3 to 24weeks; total number of sessions 30 to 196). Patient programme adherence after admission was high (85%). With reservations that eCRF follow-up data exchange remained incomplete, patient CV risk profiles experienced only small improvements. CR success as defined by an increase of exercise capacity >25W was significantly higher in young patients and those who were employed. Results differed by countries. After CR only 9% of patients were admitted to a structured post-CR programme. CONCLUSIONS: Clinical characteristics of CR patients, indications and programmes in Europe are different. Guideline adherence is poor. Thus, patient selection and CR programme designs should become more evidence-based. Routine eCRF documentation of CR results throughout European countries was not sufficient in its first application because of incomplete data exchange. Therefore better adherence of CR centres to minimal routine clinical standards is requested.
[Mh] Termos MeSH primário: Reabilitação Cardíaca
Terapia por Exercício/métodos
Diretrizes para o Planejamento em Saúde
Cardiopatias
Serviços Preventivos de Saúde
[Mh] Termos MeSH secundário: Reabilitação Cardíaca/métodos
Reabilitação Cardíaca/estatística & dados numéricos
Europa (Continente)/epidemiologia
Feminino
Fidelidade a Diretrizes
Cardiopatias/epidemiologia
Cardiopatias/reabilitação
Seres Humanos
Masculino
Meia-Idade
Seleção de Pacientes
Serviços Preventivos de Saúde/métodos
Serviços Preventivos de Saúde/organização & administração
Garantia da Qualidade dos Cuidados de Saúde
Sistema de Registros/estatística & dados numéricos
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171103
[Lr] Data última revisão:
171103
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161119
[St] Status:MEDLINE


  10 / 3965 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28025363
[Au] Autor:Ducoffe AR; York A; Hu DJ; Perfetto D; Kerns RD
[Ad] Endereço:*Previously with Office of Disease Prevention and Health Promotion (ODPHP), US Department of Health and Human Services, Washington, DC; Currently with MedStar Georgetown University Hospital, Department of Radiology, Washington, DC.
[Ti] Título:National Action Plan for Adverse Drug Event Prevention: Recommendations for Safer Outpatient Opioid Use.
[So] Source:Pain Med;17(12):2291-2304, 2016 Dec.
[Is] ISSN:1526-4637
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Adverse drug events (ADEs) have been highlighted as a major patient safety and public health challenge by the National Action Plan for Adverse Drug Event Prevention (ADE Action Plan), which was released by the Office of Disease Prevention and Health Promotion (ODPHP) in August 2014. The ADE Action Plan focuses on surveillance, evidence-based prevention, incentives, and oversights, additional research needs as well as possible measures and metrics to track progress of ADE prevention within three drug classes: anticoagulants, diabetes agents, and opioids.Objectives and Recommendations. With outpatient opioid prescriptions being a great concern among many healthcare providers, this article focuses on recommendations from the ADE Action Plan to help guide safer opioid use in healthcare delivery settings. Its aim is to discuss current federal methods in place to prevent opioid ADEs while also providing evidence to encourage providers and hospitals to innovate new systems and practices to increase prevention.
[Mh] Termos MeSH primário: Analgésicos Opioides/efeitos adversos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/prevenção & controle
Diretrizes para o Planejamento em Saúde
Política de Saúde/legislação & jurisprudência
Transtornos Relacionados ao Uso de Opioides/prevenção & controle
[Mh] Termos MeSH secundário: Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics, Opioid)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171003
[Lr] Data última revisão:
171003
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161228
[St] Status:MEDLINE
[do] DOI:10.1093/pm/pnw106



página 1 de 397 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde